Communiqués IRLAB Therapeutics AB

Actions

IRLAB A

SE0012675361

Produits pharmaceutiques

PEA

Marché Fermé - Nasdaq Stockholm 18:00:00 28/08/2026			Varia. 5j.	Varia. 1 janv.
1,788 ^SEK	+4,56 %		+4,07 %	-9,24 %

10:49	Redeye fixe une valeur cible de 6,60 couronnes pour Irlab, le partenariat reste au cœur des priorités	FW
26/08	IRLAB Therapeutics AB (publ) publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

26/08	IRLAB publishes interim report for the period January - June 2026	AQ
20/08	IRLAB: Invitation to the interim report for Q2 2026 presentation and webcast	AQ
19/08	IRLAB's Drug Candidate IRL757 Receives the Generic Name Linepemat from The WHO	AQ
19/08	IRLAB’s Drug Candidate IRL757 Receives the Generic Name linepemat from the WHO	AQ
31/07	New number of shares and votes in IRLAB Therapeutics AB	AQ
10/07	IRLAB Therapeutics : rights issue is registered – conversion of BTA into shares	PU
30/06	Report from the Annual General Meeting 2026 of IRLAB Therapeutics AB	AQ
16/06	IRLAB Presents Integrated Analysis of Mesdopetam Data at International Conference - Confirms Robust Efficacy Results in the Phase II Studies	AQ
16/06	IRLAB presents integrated analysis of mesdopetam data at international conference – confirms robust efficacy results in the Phase II studies	AQ
05/06	IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received	AQ
05/06	Report from the Extraordinary General Meeting of IRLAB Therapeutics AB	AQ
03/06	IRLAB Participates at Aktiedagarna in Stockholm on June 9	AQ
03/06	IRLAB participates at Aktiedagarna in Stockholm on June 9.	AQ
06/05	IRLAB Therapeutics : Financial Report (irlab q1 2026 eng final)	PU
06/05	IRLAB Therapeutics : publishes interim report for the period January – March 2026	PU
06/05	IRLAB publishes interim report for the period January - March 2026	AQ
05/05	IRLAB resolves on a rights issue of approximately SEK 68 million with an overallotment issue and obtains extended loan financing	AQ
30/04	IRLAB: Invitation to the interim report for Q1 2026 presentation and webcast	AQ
29/04	IRLAB publishes the Annual Report for 2025	AQ
17/04	Nomination Committee's proposal to the Board of Directors for IRLAB Therapeutics' Annual General Meeting 2026	AQ
17/04	Nomination Committee’s proposal to the Board of Directors for IRLAB Therapeutics’ Annual General Meeting 2026	AQ
09/04	IRLAB to present at Redeye Healthcare Day 2026	AQ
17/03	IRLAB to Present Clinical and Preclinical Data at The AD/PD(TM) 2026 - 20th International Conference on Alzheimer's & Parkinson's Diseases	AQ
17/03	IRLAB to present clinical and preclinical data at the AD/PD™ 2026 – 20th International Conference on Alzheimer’s & Parkinson’s Diseases	AQ
02/03	IRLAB participates in Life Science Day in Gothenburg on March 4, 2026	AQ